期刊文献+

冠心病合并非酒精性脂肪肝患者冠状动脉病变特点分析 被引量:5

Characteristics of coronary lesion in patients with coronary heart disease combined with nonalcoholic fatty liver
下载PDF
导出
摘要 目的:观察冠心病(CHD)患者非酒精性脂肪肝(NAFLD)的发病率及冠状动脉病变特点。方法纳入2011年6月~2012年12月苏北人民医院经冠状动脉造影(CAG)确诊为CHD的患者158例作为冠心病组,另纳入CAG检查结果阴性者142例作为对照组,通过肝脏彩超结果及饮酒情况比较两组NAFLD发病率。将所有患者按照是否合并NAFLD分为NAFLD组(n=158)及非NAFLD组(n=142),观察NAFLD组及非NAFLD组间病变血管数以及血管狭窄程度有无差异,同时采用放射免疫法测定一氧化氮(NO)和硝酸还原酶法测定内皮素(ET)水平,比较两组NO和ET的水平差异。结果冠心病组NAFLD发病率明显高于正常组(58.2% vs.36.6%),NAFLD患者冠脉多支病变(41.8% vs.31.1%)和重度狭窄(24.7%vs.10.6%)及完全闭塞(19.0%vs.6.3%)的比例明显高于不合并NAFLD患者(P<0.05);与非NAFLD组相比,NAFLD组NO明显下降、ET明显升高(P<0.05)。结论NAFLD对冠心病的诊断及病变程度有预测价值,其机制可能与影响内皮功能有关。 Objective To discuss the incidence of nonalcoholic fatty liver (NAFLD), characteristics of coronary lesion and possible mechanism in patients with coronary heart disease (CHD). Methods The patients (n=158) with CHD diagnosed by CAG were chosen as CHD group from the Subei People’s Hospital from Jun. 2011 to Dec. 2012. Other 142 patients with negative CAG results were chosen as control group. The incidence of NAFLD was compared according to color Doppler ultrasound and drinking status between two groups. CHD group was further divided into NAFLD sub-group (n=158) and non-NAFLD sub-group (n=142). The number of lesion vessels and degree of vascular stenosis were observed and compared between two sub-groups. The levels of nitric oxide (NO) and endothelin (ET) were detected and compared respectively by using radioimmunoassay and nitrate reductase method in two sub-groups. Results The incidence of NAFLD was significantly higher in CHD group than that in control group (58.2%vs. 36.6%). The percentages of multiple coronary vessel lesion (41.8%vs. 31.1%), severe stenosis (24.7%vs. 10.6%) and complete occlusion (19.0%vs. 6.3%) were significantly higher in NAFLD sub-group than those in non-NAFLD sub-group (P〈0.05). The level of NO decreased significantly and level of ET increased significantly (P〈0.05) in NAFLD sub-group compared with non-NAFLD sub-group. Conclusion Nonalcoholic fatty liver has predictive value to diagnosis and severity of CHD, and the mechanism may be related to endothelial function effected by NAFLD.
出处 《中国循证心血管医学杂志》 2014年第1期65-67,共3页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 冠心病 冠脉病变 非酒精性脂肪肝 内皮功能 Coronary heart disease Coronary lesion Nonalcoholic fatty liver Endothelial function
  • 相关文献

参考文献9

  • 1Chen CH,Nien CK,Yang CC,et al. Association between nonalcoholic fatty liver disease and coronary artery calcification[J]. Dig Dis Sci.,2010,55(6):1752-60.
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2117
  • 3高润霖.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志,2001,29(12):710-725. 被引量:4880
  • 4Marchesini G,Brizi M, Bianchi G,et al. Nonacoholic fatty liver disease a feature of the merablic syndrome[J]. Diabetes,2001,50(8): 1844-50.
  • 5Leoper J,Goy J,Emert J.et al. Fatty acid and lipid peroxidation in human atherosclerosis[J]. Sem Hop,1983,59(22): 1657-60.
  • 6Yun Shen,Xiaojing Ma,Jian Zhou,et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease[J]. Cardiovascular Diabetology,2013,12(1): 124.
  • 7Lin YC,Lo HM,Chen JD. Sonographic fatty liver,overweight and ischmic heart disease[J]. World J Gastroenteml,2005,11 (31):4838-42.
  • 8Ji Hoon Kang,Kyoung Im Cho,Seong Man Kim,et al. Relationship between Nonalcoholic Fatty Liver Disease and Carotid Artery Atheroselerosis Beyond Metabolic Disorders in Non-Diabetic Patients[J].J Cardiovase Ultrasound,2012,20(3):126-133.
  • 9Chia-Hung Chiang,Po-Hsun Huang,Fa-Po Chung,et al. Decreased Circulating Endothelial Progenitor Cell Levels and Function in Patients with Nonalcoholic Fatty Liver Disease[J].PLoS ONE,2012,7(2):e31799.

二级参考文献24

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:193
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献6904

同被引文献66

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部